Liver-related drug metabolism is a key aspect of pharmacokinetics
and possible toxicity. From this perspective, the availability of
advanced in vitro models for drug testing is still an open need, also
to the end of reducing the burden of in vivo experiments. In this
scenario, organ-on-a-chip is gaining attention as it couples a state-of-the
art in vitro approach to the recapitulation of key in vivo physiological
features such as fluidodynamics and a tri-dimensional cytoarchitecture.
We implemented a novel liver-on-a-chip (LoC) device based on an innovative
dynamic device (MINERVA 2.0) where functional hepatocytes (iHep) have
been encapsulated into a 3D hydrogel matrix interfaced through a porous
membrane with endothelial cells (iEndo)]. Both lines were derived
from human-induced pluripotent stem cells (iPSCs), and the LoC was
functionally assessed with donepezil, a drug approved for Alzheimer’s
disease therapy. The presence of iEndo and a 3D microenvironment enhanced
the expression of liver-specific physiologic functions as in iHep,
after 7 day perfusion, we noticed an increase of albumin, urea production,
and cytochrome CYP3A4 expression compared to the iHep static culture.
In particular, for donepezil kinetics, a computational fluid dynamic
study conducted to assess the amount of donepezil diffused into the
LoC indicated that the molecule should be able to pass through the
iEndo and reach the target iHep construct. Then, we performed experiments
of donepezil kinetics that confirmed the numerical simulations. Overall,
our iPSC-based LoC reproduced the in vivo physiological microenvironment
of the liver and was suitable for potential hepatotoxic screening
studies.